Core Insights - Ensysce Biosciences, Inc. has successfully closed a $4 million convertible preferred stock financing, with the potential for an additional $16 million in future funding over the next 24 months [1] Funding and Development - The funding will accelerate the Phase 3 clinical program for PF614, which is Ensysce's flagship analgesic candidate [1] - The capital raised will also support general corporate initiatives within the company [1]